Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ENROLLING BY INVITATION
NCT06688838
Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome
Sponsor: Tongji Hospital
View on ClinicalTrials.gov
Summary
To investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort.
Official title: Exploring the Clinical Features and Factors Related to Efficacy in Blau Syndrome: A Retrospective Observational Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
24
Start Date
2017-01-01
Completion Date
2026-12-31
Last Updated
2026-01-27
Healthy Volunteers
No
Conditions
Interventions
DRUG
Tofacitinib
If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.
Locations (1)
Yikai YU
Wuhan, Hubei, China